Jeffrey P. North
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey P. North has a total of 223 co-authors. Here are the top co-authors by number of shared publications:
- Raymond Jaihyun Cho
Department of Dermatology, University of California, San Francisco, USA
8 shared publications - Timothy H. McCalmont
Departments of Pathology and Dermatology, University of California, San Francisco, CA, USA
6 shared publications - Marina Kristy Ibraheim
Department of Dermatology, Loma Linda University, Loma Linda, CA 92354, USA
5 shared publications - Ashley A. Hailer
Department of Dermatology, University of California, San Francisco, San Francisco, CA 94107, USA
4 shared publications - Jeffrey B. Cheng
Department of Dermatology, UCSF, San Francisco, California, USA
4 shared publications Philip E. LeBoit
Departments of Dermatology and Pathology University of California San Francisco San Francisco California USA
4 shared publications
Latest Publications
- 15 October 2026
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
Trichoblastic Carcinoma Arising Within a Trichoepithelioma: A Biphasic Follicular Neoplasm With Compartment-Specific CK15, CK20, and Ki-67 Findings
Trichoblastic carcinoma (TBC) is a rare malignant follicular neoplasm whose distinction from trichoblastoma/trichoepithelioma (TE) and basal cell carcinoma may be challenging. We report an 83-year-old woman with a nodule on the left superior parietal scalp suspected clinically to be a pilar cyst. Histopathologic analysis showed a large basaloid epithelial neoplasm in the dermis and subcutis composed of variably sized nests and clusters of basaloid cells with peripheral palisading and a hypercellular fibrocytic stroma. A biphasic pattern was evident, with one component composed of small, cytologically bland cells typical of TE and a second component composed of larger cells with atypical nuclei and nuclear crowding. CK15 staining diffusely labeled the benign component and showed minimal positivity in the atypical component. CK20-positive Merkel cells colonized tumor aggregations in the benign component but not in the atypical component. The Ki-67 proliferation index was low in the bland component and elevated in the atypical component. Taken together, the findings support TBC arising within a TE. This report highlights evolution from a TE to TBC and illustrates the value of immunohistochemistry in confirming a diagnosis of TBC.
- 15 October 2026
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
Trichoblastic Carcinoma Arising Within a Trichoepithelioma: A Biphasic Follicular Neoplasm With Compartment-Specific CK15, CK20, and Ki-67 Findings
Trichoblastic carcinoma (TBC) is a rare malignant follicular neoplasm whose distinction from trichoblastoma/trichoepithelioma (TE) and basal cell carcinoma may be challenging. We report an 83-year-old woman with a nodule on the left superior parietal scalp suspected clinically to be a pilar cyst. Histopathologic analysis showed a large basaloid epithelial neoplasm in the dermis and subcutis composed of variably sized nests and clusters of basaloid cells with peripheral palisading and a hypercellular fibrocytic stroma. A biphasic pattern was evident, with one component composed of small, cytologically bland cells typical of TE and a second component composed of larger cells with atypical nuclei and nuclear crowding. CK15 staining diffusely labeled the benign component and showed minimal positivity in the atypical component. CK20-positive Merkel cells colonized tumor aggregations in the benign component but not in the atypical component. The Ki-67 proliferation index was low in the bland component and elevated in the atypical component. Taken together, the findings support TBC arising within a TE. This report highlights evolution from a TE to TBC and illustrates the value of immunohistochemistry in confirming a diagnosis of TBC.
- 29 September 2026
- Published by Wiley in Journal of Cutaneous Pathology
Inconsistent Staining for Ber‐ EP4 in Clear Cell Basal Cell Carcinoma: A Potential Diagnostic Pitfall
- 29 September 2026
- Published by Wiley in Journal of Cutaneous Pathology
Inconsistent Staining for Ber‐ EP4 in Clear Cell Basal Cell Carcinoma: A Potential Diagnostic Pitfall
- 5 January 2026
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 48 (3) , 202-204
An Acral Mixed Tumor With Histopathologic Features of Clear Cell Hidradenoma: The Value of Molecular Assessment in Challenging Cutaneous Adnexal Tumors
Cutaneous adnexal tumors are a heterogeneous group of neoplasms with diverse histopathologic features. Clear cell hidradenoma (CCH) and cutaneous mixed tumors are benign adnexal neoplasms that may share overlapping morphologic characteristics, making diagnosis challenging, particularly at uncommon acral sites. We report the case of a 60-year-old man who presented with a long-standing nodule on the hand. Histopathologic evaluation suggested a possible diagnosis of clear cell hidradenoma. There were also myxoid areas and a focal chondroid area as well, which are features seen in cutaneous mixed tumors. To further clarify the diagnosis, next-generation sequencing identified an in-frame TRPS1–PLAG1 gene fusion, confirming a diagnosis of cutaneous mixed tumor with phenotypic features of clear cell hidradenoma. This case highlights the diagnostic complexity of acral adnexal tumors with overlapping morphologic features. Molecular testing, such as next-generation sequencing, can be an essential adjunct in distinguishing between morphologically similar adnexal neoplasms, thereby guiding accurate diagnosis and management.
- 5 January 2026
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 48 (3) , 202-204
An Acral Mixed Tumor With Histopathologic Features of Clear Cell Hidradenoma: The Value of Molecular Assessment in Challenging Cutaneous Adnexal Tumors
Cutaneous adnexal tumors are a heterogeneous group of neoplasms with diverse histopathologic features. Clear cell hidradenoma (CCH) and cutaneous mixed tumors are benign adnexal neoplasms that may share overlapping morphologic characteristics, making diagnosis challenging, particularly at uncommon acral sites. We report the case of a 60-year-old man who presented with a long-standing nodule on the hand. Histopathologic evaluation suggested a possible diagnosis of clear cell hidradenoma. There were also myxoid areas and a focal chondroid area as well, which are features seen in cutaneous mixed tumors. To further clarify the diagnosis, next-generation sequencing identified an in-frame TRPS1–PLAG1 gene fusion, confirming a diagnosis of cutaneous mixed tumor with phenotypic features of clear cell hidradenoma. This case highlights the diagnostic complexity of acral adnexal tumors with overlapping morphologic features. Molecular testing, such as next-generation sequencing, can be an essential adjunct in distinguishing between morphologically similar adnexal neoplasms, thereby guiding accurate diagnosis and management.
- 10 April 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (7) , 104169
Multicenter Evaluation of Certainty and Reliability in Calciphylaxis Diagnosis Using a Digital Imaging Platform
- 10 April 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (7) , 104169
Multicenter Evaluation of Certainty and Reliability in Calciphylaxis Diagnosis Using a Digital Imaging Platform
- 12 December 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (3) , 235-243
Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status
Background: Erythroderma is a dermatologic condition characterized by widespread red and scaly skin. The causes include, but are not limited to, psoriasis, eczema, drug eruptions, pityriasis rubra pilaris (PRP), and cutaneous T‐cell lymphoma. Most of these are typified by Type 2 (e.g., eczema) or Type 17 (e.g., psoriasis) immune activation. However, since the clinicopathologic features of erythroderma can be nonspecific, assays that determine the underlying immune activation status are desirable.Methods: IL‐13 RNA in situ hybridization and IL‐36 immunohistochemistry were performed on 30 specimens of erythroderma, to ascertain Type 2 and Type 17 immune signatures, respectively.Results: Specimens of erythrodermic psoriasis and PRP showed strong expression of IL‐36 and less than one IL‐13‐positive cell per millimeter. Conversely, those of spongiotic dermatitis showed low expression of IL‐36 and greater than one IL‐13‐positive cell per millimeter. Most specimens of spongiotic, psoriasiform dermatitis demonstrated low IL‐36 expression and greater than one IL‐13‐positive cell per millimeter, but a subset showed high IL‐36 expression and greater than one IL‐13‐positive cell per millimeter.Conclusions: We developed a Type 2/17 immune signature classifier based on cytokine profiling, which showed that cases of erythroderma fall within distinct categories of immune activation. This categorization may have utility in guiding clinical decisions.
- 12 December 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (3) , 235-243
Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status
Background: Erythroderma is a dermatologic condition characterized by widespread red and scaly skin. The causes include, but are not limited to, psoriasis, eczema, drug eruptions, pityriasis rubra pilaris (PRP), and cutaneous T‐cell lymphoma. Most of these are typified by Type 2 (e.g., eczema) or Type 17 (e.g., psoriasis) immune activation. However, since the clinicopathologic features of erythroderma can be nonspecific, assays that determine the underlying immune activation status are desirable.Methods: IL‐13 RNA in situ hybridization and IL‐36 immunohistochemistry were performed on 30 specimens of erythroderma, to ascertain Type 2 and Type 17 immune signatures, respectively.Results: Specimens of erythrodermic psoriasis and PRP showed strong expression of IL‐36 and less than one IL‐13‐positive cell per millimeter. Conversely, those of spongiotic dermatitis showed low expression of IL‐36 and greater than one IL‐13‐positive cell per millimeter. Most specimens of spongiotic, psoriasiform dermatitis demonstrated low IL‐36 expression and greater than one IL‐13‐positive cell per millimeter, but a subset showed high IL‐36 expression and greater than one IL‐13‐positive cell per millimeter.Conclusions: We developed a Type 2/17 immune signature classifier based on cytokine profiling, which showed that cases of erythroderma fall within distinct categories of immune activation. This categorization may have utility in guiding clinical decisions.
- 8 October 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (1) , 48-53
The Association of Interleukin‐36 Staining Intensity and Response to Biologic Therapy in Patients With Psoriasis: A Retrospective Immunohistochemical and Chart Review Pilot Study
Background: There are limited surrogate biomarkers to identify the active inflammatory pathway in psoriasis to direct treatment with targeted biologic therapies. We investigated the association of interleukin (IL)‐36 epidermal expression, a diagnostic marker of psoriasis, with response to biologic therapy in patients with psoriasis.Methods: Retrospective immunohistochemical and chart review pilot study.Results: Patients with psoriasis with low (scores 0–2) vs. high (scores 3–4) IL‐36 expression did not have significantly different response rates to tumor necrosis factor α (TNFα), IL‐17, and IL‐12/23 or IL‐23 inhibitors; and similarly, mean IL‐36 expression scores did not significantly differ among responders vs. non‐responders to each treatment mechanism. However, in patients with psoriasis treated with IL‐12/23 or IL‐23 inhibitors, there was a marked absolute difference in response rates in those with high vs. low IL‐36 (84% vs. 50%, p = 0.12) and in mean IL‐36 scores in responders vs. non‐responders (3.35 vs. 2.57, p = 0.19).Conclusions: Patients with psoriasis with high IL‐36 expression were more likely to respond to IL‐12/23 and IL‐23 inhibition than those with low IL‐36, though these findings were not statistically significant. Additional studies with larger sample sizes are needed to validate and expand upon these findings.
- 8 October 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (1) , 48-53
The Association of Interleukin‐36 Staining Intensity and Response to Biologic Therapy in Patients With Psoriasis: A Retrospective Immunohistochemical and Chart Review Pilot Study
Background: There are limited surrogate biomarkers to identify the active inflammatory pathway in psoriasis to direct treatment with targeted biologic therapies. We investigated the association of interleukin (IL)‐36 epidermal expression, a diagnostic marker of psoriasis, with response to biologic therapy in patients with psoriasis.Methods: Retrospective immunohistochemical and chart review pilot study.Results: Patients with psoriasis with low (scores 0–2) vs. high (scores 3–4) IL‐36 expression did not have significantly different response rates to tumor necrosis factor α (TNFα), IL‐17, and IL‐12/23 or IL‐23 inhibitors; and similarly, mean IL‐36 expression scores did not significantly differ among responders vs. non‐responders to each treatment mechanism. However, in patients with psoriasis treated with IL‐12/23 or IL‐23 inhibitors, there was a marked absolute difference in response rates in those with high vs. low IL‐36 (84% vs. 50%, p = 0.12) and in mean IL‐36 scores in responders vs. non‐responders (3.35 vs. 2.57, p = 0.19).Conclusions: Patients with psoriasis with high IL‐36 expression were more likely to respond to IL‐12/23 and IL‐23 inhibition than those with low IL‐36, though these findings were not statistically significant. Additional studies with larger sample sizes are needed to validate and expand upon these findings.
- 31 August 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (4) , 251-253
The association of interleukin‐36 staining intensity with histopathologic findings of eosinophil count and spongiosis in patients with psoriasis: A secondary analysis of a retrospective immunohistochemical and chart review pilot study
- 31 August 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (4) , 251-253
The association of interleukin‐36 staining intensity with histopathologic findings of eosinophil count and spongiosis in patients with psoriasis: A secondary analysis of a retrospective immunohistochemical and chart review pilot study
- Open Access
- 12 August 2024
- Published by MDPI AG in Dermatopathology
- Vol. 11 (3) , 230-237
Interleukin-36 Is Highly Expressed in Skin Biopsies from Two Patients with Netherton Syndrome
Netherton syndrome (NS) is a rare autosomal recessive disorder that occurs due to a loss-of-function mutation in SPINK5; this loss results in significant inflammation, as well as perturbations of the skin barrier’s integrity and functionality. While it is unclear which inflammatory pathways contribute to the development of NS, recent studies have demonstrated the expression of interleukin (IL)-17/IL-36, as well as several Th2 cytokines. Consequently, immunohistochemistry (IHC) with IL-36 may serve as a potential tool for aiding the histopathological diagnosis of this condition. In this case series, we present two cases of NS and capture their immunostaining pattern with IL-36. Both cases demonstrated robust expression of IL-36. This finding bolsters the hypothesis that NS is partially driven by Th17 activation and suggests the potential utility of IL-36 IHC as part of the workup for this rare and diagnostically elusive entity. LEKTI IHC was negative in one biopsy, revealing a limitation of this stain in diagnosing NS.
- 12 August 2024
- Published by MDPI AG in Dermatopathology
- Vol. 11 (3) , 230-237
Open AccessInterleukin-36 Is Highly Expressed in Skin Biopsies from Two Patients with Netherton Syndrome
Netherton syndrome (NS) is a rare autosomal recessive disorder that occurs due to a loss-of-function mutation in SPINK5; this loss results in significant inflammation, as well as perturbations of the skin barrier’s integrity and functionality. While it is unclear which inflammatory pathways contribute to the development of NS, recent studies have demonstrated the expression of interleukin (IL)-17/IL-36, as well as several Th2 cytokines. Consequently, immunohistochemistry (IHC) with IL-36 may serve as a potential tool for aiding the histopathological diagnosis of this condition. In this case series, we present two cases of NS and capture their immunostaining pattern with IL-36. Both cases demonstrated robust expression of IL-36. This finding bolsters the hypothesis that NS is partially driven by Th17 activation and suggests the potential utility of IL-36 IHC as part of the workup for this rare and diagnostically elusive entity. LEKTI IHC was negative in one biopsy, revealing a limitation of this stain in diagnosing NS.
- 6 June 2024
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 46 (8) , 549-551
IL-36 Staining Distinguishes Clear Cell Acanthoma From Psoriasis
- 6 June 2024
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 46 (8) , 549-551
IL-36 Staining Distinguishes Clear Cell Acanthoma From Psoriasis
- 30 April 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 51 (8) , 618-623
Utility of IL‐36 immunostaining in distinguishing psoriasis from pityriasis rosea and pityriasis lichenoides
Background: Psoriasis is an inflammatory skin disease driven by upregulation of cytokines in the Th17 pathway, including interleukin‐36 (IL‐36). Previous studies have highlighted the utility of IL‐36 immunostaining for psoriasis compared to spongiotic dermatitis and other psoriasiform dermatoses; however, no study has examined the role of IL‐36 staining in distinguishing psoriasis from pityriasis rosea (PR) and pityriasis lichenoides (PL), known histologic mimickers of psoriasis.Methods: We compared the immunostaining pattern of IL‐36 for 21 PR cases, 22 PL cases, and 10 psoriasis cases. We graded the immunostaining as 0, negative; 1, focal weak; 2, diffuse weak; 3, focal, strong; or 4, diffuse strong. We further categorized stains as negative (0–2 score) or positive (3–4 score) and utilized Fisher's exact test to compare the immunostaining pattern of these entities.Results: All psoriasis specimens were positive for IL‐36, whereas all PR specimens were negative (p = 0.00000002). Twenty PL specimens were negative (p = 0.000001). Nine of 10 pityriasis lichenoides et varioliformis acuta cases were negative (p = 0.00012), and 11 of 12 cases of pityriasis lichenoides chronica were negative (p = 0.00003).Conclusions: Our findings highlight the potential role of IL‐36 immunostaining in distinguishing psoriasis from other psoriasiform dermatoses, including PR and PL.
- 30 April 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 51 (8) , 618-623
Utility of IL‐36 immunostaining in distinguishing psoriasis from pityriasis rosea and pityriasis lichenoides
Background: Psoriasis is an inflammatory skin disease driven by upregulation of cytokines in the Th17 pathway, including interleukin‐36 (IL‐36). Previous studies have highlighted the utility of IL‐36 immunostaining for psoriasis compared to spongiotic dermatitis and other psoriasiform dermatoses; however, no study has examined the role of IL‐36 staining in distinguishing psoriasis from pityriasis rosea (PR) and pityriasis lichenoides (PL), known histologic mimickers of psoriasis.Methods: We compared the immunostaining pattern of IL‐36 for 21 PR cases, 22 PL cases, and 10 psoriasis cases. We graded the immunostaining as 0, negative; 1, focal weak; 2, diffuse weak; 3, focal, strong; or 4, diffuse strong. We further categorized stains as negative (0–2 score) or positive (3–4 score) and utilized Fisher's exact test to compare the immunostaining pattern of these entities.Results: All psoriasis specimens were positive for IL‐36, whereas all PR specimens were negative (p = 0.00000002). Twenty PL specimens were negative (p = 0.000001). Nine of 10 pityriasis lichenoides et varioliformis acuta cases were negative (p = 0.00012), and 11 of 12 cases of pityriasis lichenoides chronica were negative (p = 0.00003).Conclusions: Our findings highlight the potential role of IL‐36 immunostaining in distinguishing psoriasis from other psoriasiform dermatoses, including PR and PL.